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Summary The distribution of Gp 170, a multidrug resistance (MDR) associated glycoprotein, also called
P-glycoprotein (P-gp), was examined by immunohistochemistry, using C219 and MRK16 monoclonal
antibodies. Sixty-five tumour tissues were studied which included 40 non-lymphoid tumours, 15 chemoresistant
non-Hodgkin's lymphomas and 10 Hodgkin's disease. The study was performed on both cryostat and special
fixation processed and paraplast embedded (ModAMeX) sections. The latter method preserves fixation-
sensitive antigens such as P-gp and allows a more precise morphological identification of neoplastic and
non-neoplastic cell populations in contrast to cryostat sections. Immunohistochemical expression of P-gp was
expected and confirmed in many non-lymphoid tumours, but stromal macrophages and endothelial cells were
also frequently stained in these cases. In non-Hodgkin's lymphomas, cells that were stained with both C219
and MRK16 monoclonal antibodies on cryostat sections were identified as macrophages and endothelial cells
and not neoplastic lymphoid cells, by the ModAMeX technique. These findings suggest that the quantitative
assessment of MDR RNA by Northern blotting performed on fresh homogenates overestimates the MDR
content of neoplastic cells in a number of lymphoid and non-lymphoid tumours. In addition, the mechanism
of chemoresistance in non-Hodgkin's lymphomas is less likely to be associated with P-gp expression.
One of the critical limitations in cancer chemotherapy is the
presence of either intrinsic, or acquired, drug-resistant
population of tumour cells. Multidrug resistance (MDR), is
most frequently characterised in vitro by an increase of drug
efflux and a decrease of drug accumulation in resistant cells,
compared to their drug-sensitive parental cells. Concomitant
amplification of the human MDR 1 gene, and hence the over
expression of a 170 KDa surface membrane glycoprotein,
Gp 170, also called P-glycoprotein (P-gp), is usually cor-
related with MDR (Bradley et al., 1988; Kaye, 1988).
P-gp expresion has been evaluated in many tumour sam-
ples, either by using quantitation of MDR 1 RNA by hy-
bridisation probes (Fojo et al., 1987a, 1987b; Goldstein et al.,
1989; Moscow et al., 1989) or by the measurement of P-gp
over expression by immunoblot using monoclonal antibodies
(MoAb) (Bell et al., 1985; Gerlach et al., 1987). P-gp expres-
sion has been found to be elevated in untreated intrinsically
drug-resistant tumours, such as colon or renal carcinomas
and in some recurrent but originally chemosensitive cancers
that include non-Hodgkin's lymphomas (Goldstein et al.,
1989; Moscow et al., 1989).
However, the cellular heterogeneity of P-gp expression as
recently identified in experimental models (Shen et al., 1988),
is not clearly apparent by molecular techniques performed
with the bulk tumour. Since the presence of resistant cell
clusters among a given cell population may influence the
clinical outcome of patients, it may be important to use
investigational techniques that identify a minority of P-gp
expressing cells (Marie et al., 1989). Immunohistochemistry
offers the advantages of processing routine specimens and is
generally considered to be a reliable, sensitive and rapid
method for characterising glycoproteins in the cell mem-
branes of tumour cells (Delsol et al., 1989).
Few immunohistochemical studies have yet emphasised the
P-gp expression in human tumour biopsy specimens (Salmon
et al., 1989; Dalton et al., 1989; Sugawara et al., 1989).
Moreover, these studies have usually been performed with
cryostat preparations. In our experience, the precise morpho-
logical identification of immunostained cells can be difficult,
especially in lymphoid tumours. Several MoAb directed
against P-gp have been generated (Kartner et al., 1985;
Hamada & Tsuruo, 1986; Scheper et al., 1988). Among these,
MRK16 and C219 MoAb were the most extensively used
(Thiebaut et al., 1987; Sugawara et al., 1988; Thiebaut et al.,
1989). We investigated the reactivities of both C219 and
MRK16 MoAb in 65 tumour specimens by using both cryo-
stat and paraplast-embedded preparations. The latter techni-
que combines excellent morphology with preservation of
most glycoprotein surface antigens (Delsol et al., 1989).
Unexpected expression of P-gp by stromal cells, such as
macrophages and endothelial cells was found with this tech-
nique. The finding should lead to a reconsideration of the
significance of Northern blot for exploring P-gp expression in
human cancers.
Materials and methods
Tumour specimens andpatient selection
Most tissues were retrieved from our tissue bank with storage
temperature of - 80°C. Forty solid tumour samples, which
included 5 sarcomas, 23 carcinomas and 12 others, were
tested (Table I). The clinical outcome (chemotherapy sen-
sitivity) in these cases was not determined. Ten biopsies of
Hodgkin's disease were studied (Table II). The first eight
patients were in complete remission after 3 to 12 ABVD or
MOPP cycles whereas 2 patients were in progressive disease.
Fifteen cases of non-Hodgkin's lymphomas were enrolled in
this study (Table III). The patients were selected for their
chemoresistance to drug regimens which included both
adriamycin and vincristine, known to induce P-gp expression.
The lymphomas had been previously phenotyped by standard
procedures on cryostat sections by a panel of anti-B anti-T
cluster designated monoclonal antibodies (data not shown).
In 6 cases (cases I to 6), lymph node biopsies were performed
for diagnosis. These patients later became fully resistant to 6
to 12 cycles of CHOP-B/M-BACOD front line therapy. In 0
other cases (cases 7 to 15), biopsy specimens had been
obtained from patients who were previously treated with 2 to
7 cycles of COP/CHOP-B/M-BACOD and were in relapse at
the time of the study, the patients later becoming resistant to
salvage therapy.
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Table I Non-lymphoid tumours (P-gp staining)
P-gp staininga
Neo Mac End
No Histological type C219 MRK16 C219 MRK16 C219 MRK16
1 Unclassified sarcoma 0 0 0 0 0 0
2 Rhabdomyosarcoma 0 0 0 0 0 0
3 Rhabdomyosarcoma 0 0 0 0 0 0
4 Leiomyosarcoma 0 0 0 0 2M 2M
5 Leiomyosarcoma 0 0 0 0 0 0
6 Colon carcinoma 0 0 3M 2M 0 0
7 Colon carcinoma 0 0 0 0 0 0
8 Carcinoma of unknown origin IW 1W 0 0 0 0
9 Carcinoma of unknown origin 1W 1W 0 0 0 0
10 Gastric carcinoma 0 0 0 0 0 0
11 Gastric carcinoma 0 0 0 0 0 0
12 Gastric carcinoma 0 0 0 0 0 0
13 Small intestine carcinoma iM iM 0 0 0 0
14 Renal cell carcinoma iM 1W 0 0 0 0
15 Renal cell carcinoma 35 35 0 0 0 0
16 Renal cell carcinoma 2W 2W 0 0 0 0
17 Ovarian carcinoma 25 25 0 0 0 0
18 Breast carcinoma 0 0 0 0 0 0
19 Breast carcinoma 0 0 0 0 0 0
20 Non-small cell lung carcinoma 0 0 2M 2M 0 0
21 Non-small cell lung carcinoma 0 0 0 0 0 0
22 Non-small cell lung carcinoma 0 0 0 0 0 0
23 Non-small cell lung carcinoma 0 0 0 0 0 0
24 Prostate carcinoma 0 0 2M 2M 0 0
25 Prostate carcinoma 0 0 2M 2M 0 .0
26 Prostate carcinoma 0 0 2M 2M 0 0
27 Thyroid carcinoma 0 0 0 0 0 0
28 Liver-cell carcinoma 2M 2M 25 25 0 0
29 Astrocytoma 25 25 25 25 0 0
30 Astrocytoma 0 0 35 35 35 2M
31 Plasmocytoma 0 0 2W 2W 0 0
32 Wilm's tumour 2W 2W 0 0 0 0
33 Phaeochromocytoma 0 0 iM 25 0 0
34 Phaeochromocytoma 0 0 2M 2M 0 0
35 Carcinoid tumour 0 0 25 25 0 0
36 Melanoma 0 0 2W 2W 0 0
37 Melanoma 0 0 2W 2W 0 0
38 Melanoma 0 0 35 25 0 0
39 Skin myelomonocytic tumour 25 25 0 0 0 0
40 Breast fibroadenoma 2W 2W 0 0 0 0
'P-gp staining: Neo = neoplastic cells, Mac = macrophages. End = endothelial cells. Number of
positive cells: 0 = no positive cell, I = < 10% positive cells; 2 = 10-75% positive cells, 3 = >75%
positive cells. Intensity of staining: W =weak, M = moderate, S = strong.
Table II Hodgkin's disease, clinical data and results of P-gp staining
P-gp staining'
Neo Mac End
No Sex-Age Grade Stage Therapya Response" C219 MRK16 C219 MRK16 C219 MRK16
I F-49 3 IVBb MOPPx6 CR 0 0 35 35 0 0
ABVDx6
2 M-42 I IIIAa MOPPx3 CR 0 0 2W 2W 0 0
ABVDx3
3 M-24 2 IllBb MOPPx3 CR 0 0 2W 2W 0 0
ABVDx3
RT
4 F-18 2 IIlBb MOPPx3 CR 0 0 2W 2W 0 0
ABVDx3
RT
5 M-27 2 IIlBb MOPPx3 CR 0 0 0 0 0 0
ABVDx3
RT
6 M-27 2 IlAb MOPPx3 CR 0 0 0 0 0 0
RT
7 M-61 2 IIIBb MOPPx3 CR 0 0 0 0 0 0
ABVDx3
8 F-30 2 IIAa MOPPx3 CR 0 0 0 0 0 0
RT
9 F-42 2 IVBb MOPPx6 PD 0 0 2M 2M iM iM
ABVDx6
RT
10 M-62 Nd IVBb MOPPx6 PD 0 0 0 0 0 0
ABVDx6
Nd = not determined, CR = complete response, PD = progressive disease. aMOPP = Mustine, Vincristine, Procarbazine, Prednisone.
ABVD = Adriamycin, Bleomycin, Vinblastine, Dacarbazine. RT = Radiotherapy. bResponse evaluated at the end of the chemotherapy. cp gp
staining: key in Table I.P-GP IN CANCER 179
Table III Non-Hodgkin's lymphomas, clinical data and results of P-gp staining
P-gp staining
Therapyb Neo Mac End
No Sex-Age Histologya a b C219 MRKJ6 C219 MRK16 C219 MRK16
I F-59 F no M-BACODx6 0 0 35 35 0 0
2 M-67 B no CHOP-Bx6 0 0 0 0 0 0
3 M-69 G no CHOP-Bx4 0 0 2M 2M 0 0
4 F-75 H no CHOP-Bx7 0 0 2M 2M 1W IW
5 M-50 H no CHOP-Bx8 0 0 2M 2W 0 0
6 M-66 E no CHOP-Bx4 0 0 0 0 IW IW
7 M-52 H M-BACODx6 CHOP-Bx6 0 0 0 0 0 0
8 F-56 H CHOP-Bx6 M-BACODxl 0 0 2M 2M 0 0
9 M-53 G M-BACODx6 CHOP-Bx4 0 0 25 25 2W 2W
10 M-59 E CHOP-Bx6 M-BACODx6 0 0 IM IW iM IM
11 F-65 F CHOP-Bx6 M-BACODx9 0 0 IM IM 0 0
12 F-52 C CHOP-Bx7 M-BACODx2 0 0 35 35 0 0
13 M-71 C CHOP-Bx6 M-BACODx4 0 0 0 0 0 0
14 F-41 G COPx2 M-BACODx5 0 0 25 25 0 0
15 F-55 A COPx2 CHOPx6 0 0 25 25 0 0
aHistology was given according to the Working Formulation (Anonymous, 1982): A = lymphocytic lymphoma, B = follicular small cleaved
cell lymphoma, C = follicular small and large cell lymphoma, E = diffuse small cleaved cell lymphoma, F = diffuse mixed lymphoma,
G = diffuse large cell lymphoma, H = immunoblastic lymphoma. bTherapy (a) before and (b) after the lymph node biopsy studied here. A or
H = adriamycin, B = bleomycin, C = cyclophosphamide, D = dexamethasone, M = methotrexate, D = vincristine, P = prednisone. c1pgp
staining: key in Table I.
Non-tumour tissues
Adrenal, kidney and liver tissue specimens, freshly obtained
from necropsies, were investigated for comparison of known
P-gp expression. P-gp expression has been reported to occur
on normal adrenal cortical and medullary cells, apical por-
tion of proximal tubular cells of the kidney, and canalicular
surface of hepatocytes (Thiebaut et al., 1987).
Four cases of benign lymph nodes (3 sarcoidosis and 1
reactive lymphadenitis) and a normal spleen from a case of
incidental splenectomy were included in the study.
Cell lines
Parental Chinese hamster ovary (CHO) cell line (Aux BI)
and the MDR CHRC5 subline (Kartner et al., 1985), kindly
provided by Dr R.M. Baker (RPMI, Buffalo, NY), as well as
the parental human KB-3-1 and the adriamycin resistant
sublines KB-ADRR_5A and KB-Al (Pastan & Gottesman,
1987), a generous gift of Dr M. Gottesman (NCI. Bethesda,
MD), were used as negative and positive controls.
Monoclonal antibodies
Two MoAb, C219 (Centocor, Malvern) directed against an
internal epitope of P-gp (Kartner et al., 1985) and MRK16,
which reacts with the external region of the molecule
(Hamada et al., 1986), were used. Two CD68 monoclonal
antibodies (Y2/131 from Dr D.Y. Mason, Oxford, UK &
KP-1 from Dakopatts, Copenhagen, Denmark) with major
cellular reactivity against macrophage-associated antigen
(gpl 1O) were used for investigation of the nature of stromal
cells. Negative controls were used by the omission of the
primary antibody. Simultaneous staining of several different
sections with the same antibody served as mutual control.
Immunohistochemical techniques
Tissues preparation Histological specimens were obtained
from the operating room within one hour of resection. Speci-
mens were sliced into three parts. One part was fixed in
ethanol based Bouin's fluid (Dubosq-Brazil) and processed
for routine histopathology. The second part was snap-frozen
in liquid nitrogen and stored at - 80°C until used. The third
part was processed according to the ModAMeX method, a
modification of the AMeX method (Sato et al., 1986), de-
scribed recently in detail elsewhere (Delsol et al., 1989).
Briefly, tissues for the ModAMeX method were sliced ap-
proximately 2-3 mm thick for fixation in cold acetone at 4°C
containing protease inhibitors. Fragments were then usually
left at - 20°C to fix overnight. Tissues were then dehydrated
in acetone-containing protease inhibitors at 4°C for 15
minutes followed by immersion in acetone at room
temperature for 15 minutes. Sections were cleared in mnethyl
benzoate for 15 minutes and subsequently in xylene for 15
minutes. Embedding was performed in a low melting point
paraplast (X-Tra, Carlo, Erba).
Immunostaining procedure A method for cryostat sections
has been described previously (Laurent et al., 1986). The
ModAMeX preparations were warmed to 54°C for 2 minutes
before deparaffinisation in xylene for 10 minutes. Sections
were then immersed in acetone for 4 minutes, in either
Tris-buffered saline (TBS) plus acetone or phosphate buffered
saline (PBS) plus acetone for 2 minutes followed by immer-
sion in TBS or PBS for 4 minutes and finally in TBS or PBS
plus bovine albumin (1%) for 4 minutes. Both cryostat and
ModAMeX sections were stained by the APAAP method
(Cordell et al., 1984). MRK16 and C219 MoAb were used at
4;tgml-' final concentrations. All sections were read by one
of us (GD) in batches. Even though no quantitation could be
applied to the assessment of staining reactivities, the intensity
of the reaction product could be semi-objectively classified as
weak, moderate or strong which is the notation that has been
used in the presentation of results.
Cell lines CHO and KB cell lines were suspended in culture
medium and centrifuged (14g for 5 minutes) with cytospin 2
(Shandon Inc, Pittsburgh, PA). After fixation with undiluted
acetone and chloroform for 15 minutes, the cell lines were
processed in the same manner as tissues for cryostat sections
as well as by immunoperoxidase (Laurent et al., 1986) and
APAAP techniques (Cordell et al., 1984).
Results
The feasibility of immunohistochemical assessment of the
reactivities of MoAb against P-gp was first confirmed with
the cell lines. The parental cell lines, CHO Aux Bl and
KB-3-1 were negative for both C219 and MRK16 MoAb
whereas strong positive reactions were obtained with resistant
cell lines, CHO MDR CHRC5 as well as KB-ADRR-5A and
KB-Al (adriamycin-resistant) (data not shown).
Positive staining, denoting P-gp expression by neoplastic
cells of non-lymphoid tumours, was obtained in 12 out of 40
cases (30%), namely, in renal-cell carcinoma, liver-cell car-180 D. SCHLAIFER et al.
cinoma, ovarian cacinoma, astrocytoma, Wilm's tumour,
cutaneous localisation of an acute myelomonocytic leukaemia
and a breast fibroadenoma (Table I). In the P-gp expressing
tumours, malignant cells were diffusely stained with variable,
but generally moderate intensity. The pattern of reactivities
of neoplastic cells bore no relation to the type of the neo-
plasm. We were surprised to find exclusive positivity on
macrophages, with the two anti-P-gp antibodies, in 13 out of
40 cases. In these cases, where P-gp expression was solely
encountered on macrophages, the neoplastic cells were com-
pletely negative. The intensities of the reaction product on
the macrophages varied between tumour types but were com-
parable for a given tumour for the two antibodies. In two
instances (liver cell carcinoma and astrocytoma), P-gp expres-
sion was found on both neoplastic cells and macrophages
(Table I). P-gp was expressed exclusively by some endothelial
cells only in one instance (leiomyosarcoma) and simul-
taneously with macrophages in one other case (astrocytoma).
In ten cases of Hodgkin's disease (8 chemosensitive and 2
chemoresistant), Reed-Sternberg cells were unstained in all
cases while macrophages and endothelial cells were reactive
with both C219 and MRK16 MoAb in five cases. The
number of cases in each histological type are too few to draw
meaningful correlation with histopathological subtypes.
In non-Hodgkin's lymphomas, a clear immunostaining, but
with a variable proportion of cells in each case, was obtained
with both C219 and MRK16 MoAb in 13 out of 15 cases
(86%) on cryostat sections. Positive cells were either in small
clusters or scattered throughout microscopic fields. The
intensity of the immunostaining varied but was often strong.
Accurate cytological identification of stained cells remained
uncertain on cryostat sections. However, these immunoreac-
tive cells were positively identified as macrophages in
ModAMeX prepared sections (Figure 1). In addition to the
characteristic morphology, some immunostained cells showed
tingible bodies in their cytoplasm. The neoplastic lymphoid
cells were clearly negative in all cases of non-Hodgkin's
lymphoma (Table III). The reactivity of macrophages by
anti-P-gp antibodies was further confirmed by simultaneous
staining of serial sections in three cases with CD68 antibodies
(Figure 2). It needs to be noted though, that the proportion
of macrophages stained with the CD68 was greater than
those stained by the two anti-P-gp MoAb.
Five specimens of non-malignant lymphoid tissue (3) sar-
coidosis, 1 non-specific reactive lymphadenitis, and I normal
spleen) were examined. Normal and reactive lymphocytes
were negative for P-gp expression both in lymph nodes and
in the spleen. Variable and inconsistent staining was observed
on endothelial cells of capillaries in lymph node and spleen
with the two antibodies. In lymph node, but not in the
spleen, numerous epitheloid macrophages, mainly in aggre-
Figure 1 High power magnification of a case of lymphocytic
lymphoma (case no 15, Table III) showing many macrophages
strongly positive for MRK16 monoclonal antibody. Note that
lymphoma cells are clearly negative (ModAMex method with
APAAP immunostaining x 44).
gates, were strongly stained with both C219 and MRK16
MoAb similar to the findings in tumour specimens. In one
case of sarcoidosis and one case of lymphadenitis, CD68
antibodies were used on serial sections to confirm the macro-
phage nature of the P-gp expressing cells.
Figure 2 Serial sections of malignant lymphoma (case no 9,
Table III) with high content ofmacrophages. Area identified by a
blood vessel (arrow). A - Staining of macrophages, some with
vacuolated cytoplasm, by anti-P-gp, MRK16 antibody. No stain-
ing of lymphoid cells. B - Staining of a larger number of macro-
phages by Y2/131 (CD68), anti-macrophage antibody. However,
four stained cells identical to those in A are shown with
arrowheads (ModAMeX method with APAAP immunostaining
x 40).P-GP IN CANCER 181
Discussion
C219 and MRK16 have been used previously for charac-
terisation of P-gp expression in normal tissues on cryostat
sections (Thiebaut et al., 1987; Sugawara et al., 1988;
Thiebaut et al., 1989). Localisation of P-gp has been found
on biliary canalicular front of hepatocytes, apical portions of
proximal tubular cells of the kidney and diffusely in adrenal
cortical and medullary cells with the two antibodies
(Thiebaut et al., 1987; Thiebaut et al., 1989). On both cryo-
stat sections and ModAMeX processed sections we found
P-gp expression in normal tissues similar to that reported by
these authors. P-gp expression by neoplastic cells in cases of
renal-cell carcinoma, liver-cell carcinoma and ovarian car-
cinoma was expected from the reported Northern blot studies
(Fojo et al., 1987b; Goldstein, et al., 1989; Moscow et al.,
1989). In addition P-gp expression could be identified on
resistant cell lines compared to its absence on parental cell
lines. These observations confirmed the reliability of
immunohistochemical methods for studying P-gp expression
in human cancers. Moreover, the strong reactivities observed
in paraplast preparations showed that the ModAMeX techni-
que, which was essentially developed for optimal preservation
of leucocyte differentiation antigens, is equally feasible for
the immunodetection of P-gp.
Patients with non-Hodgkin's lymphoma were selected on
the basis of their resistance to drugs normally involved in the
MDR phenotype. We were surprised to find the lack of P-gp
expression by lymphoma cells in all cases. Our results are in
conflict with those reported by Salmon et al. (1989) and
Dalton et al. (1989), who found at least 50% positive cases
(3/6 and 1/1 respectively) with a biotin-avidin conjugated
immunoperoxidase method using JSB-l and C219 MoAb.
Such a discrepancy cannot be explained either by the selec-
tion of patients, or by the immunostaining methods, since, in
our experience, the APAAP technique used in our study is as
sensitive as the biotin-avidin procedure. It is possible that the
heterogeneity of the results is due to the small size of the
patient populations in previous studies. In a recent report,
Sugawara et al. (1989) did not find significant staining of
lymphoma cells by MRKl6 MoAb using flow cytometry.
Furthermore, Northern blot studies have shown that the
incidence of MDR in lymphoma patients is rather low,
accounting for only about 30% of the patients with moderate
or low MDR1 RNA levels (Goldstein et al., 1989; Moscow et
al., 1989). The latter findings are in line with our study and
suggest that drug resistance to CHOP or CHOP-derived
regimens in lymphomas could be mediated by mechanisms
other than P-gp over expression.
P-gp expression in Hodgkin's disease has not been
previously reported. In our study, Reed-Sternberg cells did
not express P-gp. However, these patients had not been
selected on the basis of their chemotherapeutic unresponsive-
ness, since 8 of 10 patients achieved complete remission after
first line MOPP/ABVD treatment. Further studies on
MOPP/ABVD resistant patients are needed to assess the
possible role of MDR in refractory Hodgkin's disease.
Interestingly, we found positivity of numerous stromal cells
in some non-lymphoid and lymphoid tumours (Figure 1) as
well as in non-tumoural inflammatory processes. In these
cases, macrophages, mainly in aggregates, were positive with
both C219 and MRK16 MoAb. The reactivity appears
specific because the two antibodies recognise two different
membrane epitopes. The findings need to be strengthened
further by in situ hybridisation with a specific MDR-1 probe
(currently in progress). P-gp was not expressed by macro-
phages in all tumours, neither did all macrophages in the
same tumour express P-gp. It is possible, therefore, that the
positivity is due to the expression of P-gp by a subset of
macrophages. In this context, cellular activation signals
involved in antitumour host responses or inflammatory pro-
cesses may trigger cells of the monocyte/macrophage system
to induce P-gp expression. The mechanism of P-gp expres-
sion by macrophages remains to be elucidated but our
findings suggest that these cells are responsible in some in-
stances for an overestimation of the MDR content of tumour
cells with Northern blot or immunoblot techniques per-
formed on fresh tissues homogenates.
Finally, this study confirms that immunohistochemistry
represents a useful tool for studying P-gp expression in
human cancers, especially if the technique used allows a
precise morphological assessment of antigen distribution and
bypasses the interpretative difficulties of cryostat sections.
However, immunomorphology does not allow exact
quantification of P-gp content. Therefore, it may be advisable
to combine immunohistochemical and molecular biology
techniques for exploring any putative correlation between
MDR expression and the clinical outcome.
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